Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
national top stories
new york blog main
new york top stories
vascepa
3
×
amarin
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
detroit blog main
detroit top stories
diabetes
heart disease
indiana blog main
indiana top stories
national
pfizer
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abeona therapeutics
acc
accent therapeutics
achilles therapeutics
acquisition
activist investor
aducanumab
What
bio
drug
medical
roundup
abuzz
adu
advantages
ago
amarin
approved
bar
beats
bids
big
biogen
brings
clinical
community
complicated
deeper
depression
dire
dive
doctors
eager
expect
fish
gamble
gives
good
group
heart
help
market
medco’s
months
mover
need
new
news
Language
unset
Current search:
vascepa
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Deeper Dive: Amarin Fish-Oil Study Gives Eager Doctors More to Ponder